Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy

Stefano Molica, Angelo Vacca, Luigi Tucci, Domenico Ribatti

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated bone marrow (BM) angiogenesis in 12 responding patients with Binet stage B chronic lymphocytic leukemia who received either chlorambucil or fludarabine. Microvessel density (MVD) was compared between pre-treatment marrow samples and those obtained after at least 4 cycles of chemotherapy. BM angiogenesis decreases in all patients but one, although subset analysis revealed the decrease of BM angiogenesis was significant only in patients who received fludarabine. Even if based on a small number of patients, these results point out the potential in vivo anti-angiogenic activity of fludarabine.

Original languageEnglish
Pages (from-to)698-700
Number of pages3
JournalHaematologica
Volume90
Issue number5
Publication statusPublished - May 2005

Keywords

  • Angiogenesis
  • CLL
  • Fludarabine

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy'. Together they form a unique fingerprint.

Cite this